A growing body of evidence implies that depression may arise in part through a deregulation of neuroplasticity, and novel antidepressants have shown therapeutic potential by exerting neurogenic and neuroplastic effects. The hematopoietic cytokine erythropoietin (EPO) has shown antidepressant potential with an ability to regulate neuroplastic and cognitive-behavioral outcomes. This research sought to further the knowledge of the antidepressant potential of EPO through cellular and behavioral outcomes. In Exp 1, effects of 2 week EPO administration on chronically stressed rodents (an animal model of depression) was observed by the forced swim test (FST) and doublecortin immunohistochemistry for immature granule cells. In Exp. 2, whether acute EPO administration has the potential to synergize with an SSRI was analyzed using the FST. This research showed no effect of EPO on cellular or behavioral outcomes, suggesting a necessity for further studies of this paradigm utilizing alternative models or methods to those used here.